2-肼基-1H-1,3-苯并咪唑 | 15108-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-肼基-1H-1,3-苯并咪唑
• 中文别名: 1H-苯并咪唑-2-基肼；苯并咪唑,2-肼基-；2H-苯并咪唑-2-酮,1,3-二氢-,腙；2-肼基-1H-苯并咪唑
• 英文名称: 2-hydrazinyl-1H-benzo[d]imidazole
• 英文别名: 2-hydrazinyl-1H-benzimidazole；2-Hydrazinobenzimidazole；1H-benzimidazol-2-yl hydrazine；1H-benzimidazole-2-yl-hydrazine；2-hydrazino-1H-benzimidazole；1H-benzimidazol-2-ylhydrazine
• CAS: 15108-18-6
• 化学式: C₇H₈N₄
• mdl: MFCD00513603
• 分子量: 148.167
• InChiKey: PXUYWNZBZXDJEU-UHFFFAOYSA-N

物化性质

• 熔点：
  224-225
• 沸点：
  318.2±25.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO（微溶，加热）、甲醇（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.7
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  -20°C下保存，请避光并置于惰性气体环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Hydrazino-1h-1,3-benzimidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Hydrazino-1h-1,3-benzimidazole
CAS number: 15108-18-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, under −20◦C.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H8N4
Molecular weight: 148.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-肼基-1H-1,3-苯并咪唑 反应 38.0h， 生成 3-methyl-1,2,4-triazolo<4,3-b>benzimidazole
  参考文献：
  名称：

  2-肼基苯并咪唑、-苯并恶唑和-苯并噻唑的缩合和环化反应

  摘要：

  2-肼基苯并恶唑 (1)、-苯并咪唑 (2) 和苯并噻唑 (3) 与氯甲酸乙酯和/或草酸二乙酯缩合生成 1,2,4-三唑并和 1,2,4-三嗪酮稠合酮分别为标题唑。1 和 2 与芳香醛和/或乙酸酐缩合，分别产生 3-芳基和 3-甲基取代的 1,2,4-三唑并稠合唑。肼 1 和 2 与乙酰丙酮环化生成相应的 2-(1-吡唑基) 衍生物。2-乙酰噻唑并苯并咪唑与羟胺和/或烷基胺反应生成相应的缩合产物。它也与芳香醛缩合得到查耳酮。与重氮苯盐反应，得到相应的2-芳基偶氮取代化合物。

  DOI：

  10.1246/bcsj.61.1339
• 作为产物：
  描述：

  (1H-苯并咪唑-2-基硫代)乙酸乙酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以63%的产率得到2-肼基-1H-1,3-苯并咪唑
  参考文献：
  名称：

  1H-苯并咪唑-2-基腙作为微管蛋白靶向剂：合成、结构表征、抗蠕虫活性和抗 MCF-7 乳腺癌细胞增殖活性和分子对接研究

  摘要：

  在本研究中，合成了 15 个苯并咪唑基-2-腙7a-7o的氟-、羟基-和甲氧基-取代的苯甲醛和 1,3-苯并二氧戊环-5-甲醛，并通过红外、核磁共振和元素分析鉴定了它们的结构. 化合物7j 2-(3-羟基苯亚甲基)-1-(5(6)-甲基-1 H-苯并咪唑-2-基)腙和7i 2-(3-羟基苯亚甲基)-1-(1 H-苯并咪唑-2基）腙都产生最强的驱虫活性（100％后，在37℃）对的分离的肌幼虫24小时温育期旋毛虫在体外实验。在体外向细胞毒性测定MCF-7乳腺癌细胞和小鼠胚胎成纤维细胞3T3表明所研究的苯并咪唑基-2-腙表现出低至中度的细胞毒性作用。所研究的苯并咪唑基-2-腙调节微管聚合的能力得到证实，并表明它们的驱虫作用是通过抑制微管蛋白聚合来介导的，与其他已知的苯并咪唑驱虫药一样。还表明，四种最有希望的苯并咪唑基-2-腙即使在高测试浓度下也不会显着影响 AChE 活性，因此表明它们不具有神经

  DOI：

  10.1016/j.cbi.2021.109540

文献信息

• Tautomerism of guanidines studied by 15N NMR: 2-hydrazono-3-phenylquinazolin-4(3H)-ones and related compounds
  作者：Ion Ghiviriga、Bahaa El-Dien M. El-Gendy、Peter J. Steel、Alan R. Katritzky

  DOI：10.1039/b907577a

  日期：——

  2-Hydrazono-3-phenylquinazolin-4(3H)-ones 11a–i are shown by 15N NMR to exist in DMSO solution predominantly as the imino tautomers B and not the amino tautomers A. 2-Hydrazino-benzimidazole derivative 12 and 2-hydrazino-4,6-dimethylpyrimidine derivative 13 were found to exist predominantly as the amino tautomers.

  2-肼叉-3-苯基喹唑啉-4(3H)-酮11a–i在DMSO溶液中主要以亚胺互变异构体B存在，而不是氨基互变异构体A，这一结论通过15N NMR得以证实。而2-肼基苯并咪唑衍生物12和2-肼基-4,6-二甲基嘧啶衍生物13则主要以氨基互变异构体形式存在。
• [EN] AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY<br/>[FR] PYRAZOLONES AMINOMÉTHYLÈNE À ACTIVITÉ THÉRAPEUTIQUE
  申请人：COMPOUND HANDLING B V

  公开号：WO2013131931A1

  公开（公告）日：2013-09-12

  A compound having the structure according to formula III wherein: X is NH or S;R1 is H or (1C-4C)alkyl;R2 is (1C-4C)alkyl, phenyl or a monocyclic aromatic ring having one or more N-, O-or S-atoms in the ring, which alkyl, phenyl or aromatic ring is optionally substituted with one or more groups selected from (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, phenyloxy, phenylthio, halogen, or nitro;R3 and R4 are each independently H, (1C-6C)alkyl, (2C-6C) alkenyl, (2C-6C)alkynyl, cyano, (3C-6C)cycloalkyl, phenyl, a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, a monocyclic non-aromatic ring having one or more N-, O- or S-atoms in the ring, each optionally substituted with hydroxyl, (1C-4C)alkoxy, phenyl, cycloalkyl, piperidyl, piperazinyl, furyl, thienyl, pirazinyl, pyrrolyl, 2H-pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrrolidonyl, pyrrolinyl, imidazolinyl, imidazolyl, a monocyclic aromatic ring having one or more N-, O- or S- atoms in the ring, whereby each of these optional substituents is optionally further substituted with (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, halogen, nitro or (1C-2C)dioxol forming a ring;or R3 and R4 form together pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyrrolinylimidazolidinyl, imidazolinyl, piperidyl, piperazinylmorpholinyl, each optionally substituted with (1C-6C)alkyl, phenyl(1C-4C)alkyl, phenylketo(1C-4C)alkyl; R5 is H, Cl, F, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; R6 is H, (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, nitro or halogen;R7 is H,F, Cl, Br, Me, NO2, t-butyl, OCF3, OCH3, CF3; or pharmaceutically acceptable addition salts thereof for use in treatments of carcinoma, in particular to delay, prevent or reverse metastasis in prostate cancer.

  具有根据式III的结构的化合物，其中：X为NH或S；R1为H或(1C-4C)烷基；R2为(1C-4C)烷基、苯基或具有环中一个或多个N、O或S原子的单环芳香环，该烷基、苯基或芳香环可以选择地被一个或多个来自(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、苯氧基、苯硫基、卤素或硝基的基团取代；R3和R4分别独立地为H、(1C-6C)烷基、(2C-6C)烯基、(2C-6C)炔基、氰基、(3C-6C)环烷基、苯基、具有环中一个或多个N、O或S原子的单环芳香环、具有环中一个或多个N、O或S原子的单环非芳香环，每个可以选择地被羟基、(1C-4C)烷氧基、苯基、环烷基、哌啶基、哌嗪基、呋喃基、噻吩基、吡嗪基、吡咯基、2H-吡咯基、吡唑基、异噁唑基、异硫唑基、吡咯烷酰基、吡咯烯基、咪唑啉基、咪唑啉基咪唑啉基、咪唑啉基、哌啶基、哌嗪基吗啉基，每个可以选择地进一步被(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、卤素、硝基或(1C-2C)二氧杂环己基取代形成环；或者R3和R4共同形成吡咯基、咪唑基、吡唑基、吡咯烷基、吡咯烯基、咪唑啉基、哌啶基、哌嗪基吗啉基，每个可以选择地被(1C-6C)烷基、苯基(1C-4C)烷基、苯基酮(1C-4C)烷基取代；R5为H、Cl、F、Br、Me、NO2、叔丁基、OCF3、OCH3、CF3；R6为H、(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、硝基或卤素；R7为H、F、Cl、Br、Me、NO2、叔丁基、OCF3、OCH3、CF3；或其在治疗癌症，特别是延迟、预防或逆转前列腺癌转移方面的药学上可接受的加合物盐。
• Aminomethylene pyrazolones with therapeutic activity
  申请人：Compound Handling B.V.

  公开号：EP2636673A1

  公开（公告）日：2013-09-11

  The invention provides for a compound having the structure according to formula I wherein: X is NH or S; R1 is H or (1C-4C)alkyl; R2 is (1C-4C)alkyl, phenyl or a monocyclic aromatic ring having one or more N-, O- or S- atoms in the ring, which alkyl, phenyl or aromatic ring is optionally substituted with one or more groups selected from (1C-4C)alkyl, (1C-4C)alkyloxy, halo(1C-4C)alkyl, halo(1C-4C)alkyloxy, phenyloxy , phenylthio, halogen, or nitro; R3 and R4 are each independently H, (1C-6C)alkyl, (2C-6C) alkenyl, (2C-6C)alkynyl, cyano, (3C-6C)cycloalkyl, phenyl, a monocyclic aromatic ring having one or more N-, O- or S- atoms in the ring, a monocyclic non-aromatic ring having one or more N-, O- or S- atoms in the ring, each optionally further substituted with hydroxyl, (1C-4C)alkoxy, phenyl, cycloalkyl, piperidyl, piperazinyl, furyl, thienyl, pirazinyl, pyrrolyl, 2H-pyrrolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrrolidonyl, pyrrolinyl, imidazolinyl, imidazolyl, a monocyclic aromatic ring having one or more N-, O- or S-atoms in the ring, whereby each of these optional substituents is optionally further substituted with (1 C-4C)alkyl, (1 C-4C)alkyloxy, halo(1 C-4C)alkyl, halo(1 C-4C)alkyloxy, halogen, nitro or (1 C-2C)dioxol forming a ring; or R3 and R4 form together pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyrrolinylimidazolidinyl, imidazolinyl, piperidyl, piperazinylmorpholinyl, each optionally substituted with (1 C-6C)alkyl, phenyl(1 C-4C)alkyl, phenylketo(1C-4C)alkyl; R5 is H or CF3; R6 is (1 C-4C)alkyl, (1 C-4C)alkyloxy, halo(1 C-4C)alkyl, halo(1 C-4C)alkyloxy, nitro or halogen; for use in treatments of carcinoma, in particular to delay, prevent or reverse metastasis in prostate cancer.

  该发明提供了一种具有以下结构的化合物，符合以下公式I： 其中： X为NH或S；R1为H或(1C-4C)烷基；R2为(1C-4C)烷基、苯基或具有环中一个或多个N、O或S原子的单环芳香环，该烷基、苯基或芳香环可以选择性地被一个或多个来自(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、苯氧基、苯硫基、卤素或硝基的基团取代；R3和R4分别独立地为H、(1C-6C)烷基、(2C-6C)烯基、(2C-6C)炔基、氰基、(3C-6C)环烷基、苯基、具有环中一个或多个N、O或S原子的单环芳香环、具有环中一个或多个N、O或S原子的单环非芳香环，每个基团可以选择性地进一步被羟基、(1C-4C)烷氧基、苯基、环烷基、哌啶基、哌嗪基、呋喃基、噻吩基、吡嗪基、吡咯基、2H-吡咯基、吡唑基、异噁唑基、异硫唑基、吡咯烷酰基、吡咯烯基、咪唑啉基、咪唑啉基咪唑啉基、咪唑啉基、哌啶基、哌嗪基吗啉基，每个基团可以选择性地进一步被(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、卤素、硝基或(1C-2C)二氧杂环己基取代形成环；或者R3和R4共同形成吡咯基、咪唑基、吡唑基、吡咯烷基、吡咯烯基、咪唑啉基、哌啶基、哌嗪基吗啉基，每个基团可以选择性地被(1C-6C)烷基、苯基(1C-4C)烷基、苯基酮(1C-4C)烷基取代；R5为H或CF3；R6为(1C-4C)烷基、(1C-4C)烷氧基、卤代(1C-4C)烷基、卤代(1C-4C)烷氧基、硝基或卤素；用于治疗癌症，特别是用于延迟、预防或逆转前列腺癌的转移。
• 3-Aryl-[1,2,4]triazino[4,3-<i>a</i>]benzimidazol-4(10<i>H</i>)-ones:  Tricyclic Heteroaromatic Derivatives as a New Class of Benzodiazepine Receptor Ligands
  作者：Giampaolo Primofiore、Federico Da Settimo、Sabrina Taliani、Anna Maria Marini、Concettina La Motta、Ettore Novellino、Giovanni Greco、Marco Gesi、Letizia Trincavelli、Claudia Martini

  DOI：10.1021/jm991131h

  日期：2000.1.1

  A series of 3-substituted [1,2,4]triazino[4,3-c]benzimidazoles V were prepared and tested at the central benzodiazepine receptor (BzR). These compounds were designed as rigid analogues of the previously described N-benzylindolylglyoxylylamide derivatives IV. The title compounds V showed an affinity which depended directly on the presence of the N(10)-H group and an aromatic ring at position 3. Some

  制备了一系列3-取代的[1,2,4]三嗪[4,3-c]苯并咪唑V，并在中央苯并二氮杂pine受体（BzR）上进行了测试。这些化合物被设计为先前描述的N-苄基吲哚基二烯丙基乙二酰胺衍生物IV的刚性类似物。标题化合物V显示出亲和力，该亲和力直接取决于N（10）-H基团和位置3上的芳环的存在。相对于吲哚基二羟乙酰胺，它们中的一些引起了2倍或3倍的高亲和力。导数IV（R = H）。GABA比和[（35）S]-叔丁基环磷酸硫代酸酯结合数据揭示了化合物1c，e，f，j，k的部分反向激动剂/拮抗剂和2c的部分激动剂的功效谱。该最后的化合物被证明可有效拮抗戊四氮诱导的小鼠癫痫发作。
• Designing Structural Motifs for Clickamers: Exploiting the 1,2,3-Triazole Moiety to Generate Conformationally Restricted Molecular Architectures
  作者：Denise Zornik、Robert M. Meudtner、Tamer El Malah、Christina M. Thiele、Stefan Hecht

  DOI：10.1002/chem.201002491

  日期：2011.2.1

  around the single bonds attached to both the 1‐ and 4‐positions of the 1,2,3‐triazole moiety and should therefore be able to induce well‐defined conformational preferences in higher oligomers and polymers, that is, foldamers. Various compounds were synthesized and characterized with regard to their preferred conformations in all three aggregation states—that is, in the gas phase, in solution as well

  限制在一个大分子中的非共价相互作用，尤其是氢键相互作用以及静电力，是设计在溶液中采用定义明确的构型的折叠剂的关键。在三唑连接的折叠剂（即所谓的Clickamers）领域近期的重要活动中，我们提出了一项基础研究，比较了带有相邻N-，O-或F-杂原子取代基的各种模型化合物。吸引和排斥相互作用的相互作用导致围绕连接于1,2,3-三唑部分的1和4位的单键周围的旋转约束，因此应能够在较高的低聚物中诱导明确定义的构象偏好和聚合物，即折叠剂。通过使用DFT计算，NMR光谱实验和X射线晶体学，合成并表征了所有化合物在所有三种聚集状态下（即气相，溶液中和固态）的优选构象，并对其进行了表征， 分别。根据对单个连接基序构象行为的一般理解，在不影响其独特折叠特性的情况下，由不同基序制备了异质结构。因此，这项工作提供了一种折叠架构造套件，该套件应能够设计出具有特定形状和所包含功能的各种Clickamer。NMR光谱